What is the recommended treatment for adult uncomplicated and severe malaria, including species-specific regimens, drug‑resistance considerations, and pregnancy precautions?

Treatment for Malaria in Adults

For uncomplicated P. falciparum malaria, treat with oral artemisinin-based combination therapy (ACT)—specifically artemether-lumefantrine or dihydroartemisinin-piperaquine as first-line agents; for severe malaria, immediately initiate intravenous artesunate regardless of trimester or pregnancy status. 1

Uncomplicated Malaria Treatment

Plasmodium falciparum (Uncomplicated)

First-line options (choose one):

• Dihydroartemisinin-piperaquine (320mg/40mg):

  • 36-75 kg: 3 tablets daily for 3 days

  • 75 kg: 4 tablets daily for 3 days

  • Take on empty stomach
  • Avoid in patients with QTc prolongation risk 1

• Artemether-lumefantrine (20mg/120mg):

  • Day 1: 4 tablets at hour 0, then 4 tablets at hour 8
  • Day 2: 4 tablets at hours 36 and 48
  • Day 3: 4 tablets at hours 60 and 72
  • Must take with fatty meal or drink
  • Can be used in all trimesters of pregnancy per WHO and CDC 1, 2

Second-line option:

• Atovaquone-proguanil (250mg/100mg): 3-4 tablets daily for 3 days depending on weight 1

Third-line (when ACTs unavailable):

• Quinine plus doxycycline or clindamycin for 7 days 1

Plasmodium vivax or P. ovale (Uncomplicated)

First-line for chloroquine-sensitive areas:

• Chloroquine: 4 tablets (1000mg salt) initially, then 2 tablets (500mg salt) at 6,24, and 48 hours 1

For chloroquine-resistant P. vivax (Papua New Guinea, Indonesia):

• Use same ACT regimens as for P. falciparum 1

Critical addition—radical cure to prevent relapse:

• Primaquine 30mg base daily for 14 days OR
• Tafenoquine 300mg single dose (not available in Europe)
• Must test for G6PD deficiency before starting—do not use if deficient 1, 3

Plasmodium malariae or P. knowlesi

First-line:

• Chloroquine: Same dosing as for P. vivax 1
• ACTs are second-line alternatives

Severe/Complicated Malaria (All Species)

Criteria for Severe Malaria

Any one of the following defines severe malaria:

• Clinical: Unarousable coma, multiple convulsions, shock, pulmonary edema, acute respiratory distress, oliguria (<400mL/24hr), jaundice with parasitemia >100,000/mL, bleeding
• Laboratory: Hemoglobin <7g/dL, acidosis, hypoglycemia (<40mg/dL), hyperparasitemia (>5% in non-immune, >10% in semi-immune), creatinine >3mg/dL 1

Note: Parasitemia thresholds vary by guideline (2-5%), but >4% is the most common criterion in European ICU admissions 1

Treatment Protocol

First-line:

• Intravenous artesunate 2.4mg/kg at 0,12, and 24 hours, then daily for up to 7 days
• Switch to oral ACT when patient can tolerate oral medication AND parasitemia <1%
• Complete full course of oral therapy (preferably ACT) 1

Second-line (if artesunate unavailable):

• Intravenous quinine dihydrochloride: 20mg salt/kg loading dose over 4 hours, then 10mg/kg every 8 hours
• Switch to oral therapy after minimum 48 hours IV treatment when feasible 1

Monitoring Requirements for Severe Malaria

• Parasitemia: Every 12 hours until <1%, then every 24 hours until negative
• Labs: Daily complete blood count, hepatic/renal function, glucose, blood gas
• Post-artesunate delayed hemolysis (PADH): Monitor on days 7,14,21, and 28 after treatment 1

Pregnancy-Specific Considerations

First Trimester

• Uncomplicated malaria: Quinine plus clindamycin traditionally recommended, but artemether-lumefantrine is now considered safe based on substantial global safety data 2, 4
• Severe malaria: Intravenous artesunate—do not delay treatment 1, 3

Second and Third Trimesters

• All ACTs are safe and effective (cure rates ≥94.9%) 2
• Artemether-lumefantrine specifically approved by WHO and CDC for all trimesters 1, 2

Critical Pregnancy Precautions

• Never use primaquine or tafenoquine during pregnancy or breastfeeding—defer radical cure until after delivery 1
• Monitor closely for hypoglycemia (quinine can cause insulin release) 1

Drug Resistance Considerations

Geographic Resistance Patterns

Chloroquine-resistant P. falciparum:

• Present in most malaria-endemic areas
• Use ACTs, not chloroquine 5, 6

Artemisinin resistance:

• Established in Greater Mekong sub-region (Southeast Asia)
• Emerging concern in other areas
• Only 3 of 13 non-endemic country guidelines adjust for resistance patterns—clinicians must consider travel history 6

Chloroquine-resistant P. vivax:

• Papua New Guinea and Indonesia
• Use ACTs instead of chloroquine 1

Practical Approach

When treating travelers, always determine the specific country/region of acquisition to assess resistance patterns and select appropriate therapy 6

Common Pitfalls to Avoid

1. Delayed diagnosis: Always obtain travel history in febrile patients—malaria causes preventable deaths when overlooked 1, 5

2. QTc prolongation: Both artemether-lumefantrine and dihydroartemisinin-piperaquine can prolong QTc—avoid in patients with baseline QTc issues or on interacting medications 1

3. Forgetting radical cure: P. vivax and P. ovale require 8-aminoquinoline (primaquine/tafenoquine) to eliminate liver hypnozoites—must test G6PD first 1, 3

4. Inadequate monitoring: Severe malaria requires ICU admission and intensive monitoring—check parasitemia every 12 hours initially 1

5. Artemether-lumefantrine dosing complexity: The 6-dose regimen over 60 hours is complicated—ensure patient understands timing and need for fatty food 1

6. Missing PADH: Post-artesunate delayed hemolysis can occur weeks after treatment—schedule follow-up monitoring 1

7. Pregnancy hesitation: Do not withhold artesunate in severe malaria during pregnancy—maternal and fetal mortality from untreated severe malaria far exceeds any theoretical drug risk 1, 3